Reuters logo
21 days ago
BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA
July 31, 2017 / 1:24 PM / 21 days ago

BRIEF-Amgen and Allergan submit biosimilar Biologics License application for ABP 980 to U.S. FDA

July 31 (Reuters) - Amgen Inc

* Amgen and Allergan submit biosimilar Biologics License Application for ABP 980 to US Food and Drug Administration

* Amgen - Co and Allergan are collaborating on four oncology biosimilar medicines, including ABP 980 which is second to be submitted for FDA approval​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below